Ashutosh Tewari, MD
- PROFESSOR AND SYSTEM CHAIR | Urology
Ashutosh (Ash) K. Tewari, MD, Chairman, Milton and Carroll Petrie Department of Urology at the Icahn School of Medicine at Mount Sinai is a world-renowned urologist and prostate cancer specialist. As Director of the Department of Urology, he leads a multidisciplinary team committed to improving prostate cancer treatment, research and education. To date, he has performed over 5,000 robotic radical prostatectomy surgeries. The Tewari Lab is working on unlocking the genomic causes of prostate cancer and translating genomic information to practical physician application through imaging. In 2012, he was awarded the American Urological Association’s Gold Cystoscope Award. This honor is given annually to the urologist who has contributed significantly to the field within 10 years of completing residency. Dr. Tewari holds several leadership positions domestically and internationally.
Dr. Tewari received his undergraduate and medical degrees at GSVM Medical College (Kanpur, India). During medical school he was awarded 17 Gold Medals for outstanding performance on university exams. Dr. Tewari completed his first urology residency at Sanjay Gandhi Post Graduate Institute of Medical Sciences (Lucknow, India). He completed fellowships in urologic-oncology at University of California, San Francisco and the University of Florida (Gainesville, FL). In 2004, he completed his second urology residency at Henry Ford Hospital (Detroit, Michigan). While at Henry Ford, Dr. Tewari was part of the team that performed the first robotic radical prostatectomy in the United States.
Dr. Tewari’s case series is one of the largest in the world and his outcomes are considered the gold standard for this procedure. Dr. Tewari’s clinical expertise in prostate cancer includes targeted biopsies, cystoscopies, robotic prostatectomies, as well as the management of active surveillance prostate cancer patients. He has also initiated clinical protocols investigating the utility of focal therapy platforms for the treatment of prostate cancer. Dr. Tewari has been consecutively listed in New York Magazine’s Top Doctors issue since 2006. Learn more at his Center for Prostate Cancer website.
Dr. Tewari’s research approaches the problem of prostate cancer from distinct perspectives.
His outcomes research group is investigating the epidemiological effects of prostate cancer. He is also investigating several novel imaging techniques for identifying prostate cancer imaging biomarkers. And Dr. Tewari is working to unlock the genomic causes of prostate cancer.
As a researcher, Dr. Tewari has authored over 250 peer-reviewed articles, book chapters, and textbooks on prostate cancer and robotic surgery. This includes several high-impact articles in Nature, Cell, and PNAS. Most recently he has edited Prostate Cancer: A Comprehensive Perspective (Elsevier 2013).
In addition to his publications, Dr. Tewari is the recipient of three major NIH Federal research awards. This includes an R01 grant, in which he serves as Principal Investigator, investigating the utility of multiphoton microscopy during prostate cancer treatment. Dr. Tewari also serves as site-PI for the NIH/NCI The Cancer Genome Atlas Tissue Source Site and the NIH/NCI Early Detection Research Network. In addition to his Federal funding, Dr. Tewari is currently funded by the Prostate Cancer Foundation, Boston Scientific, and Medtronic. He has initiated collaborative work with several other leading institutions including Cold Spring Harbor Laboratory, the Broad Institute of MIT and Harvard, The Koch Institute for Integrative Cancer Research at MIT, Dana-Farber Cancer Institute, and Rockefeller University,
Dr. Tewari has trained over 30 fellows and residents in robotics. His fellows have gone on to establish successful prostate cancer programs in Canada, Great Britain, India, Japan and Singapore. Dr. Tewari hosts an annual international prostate cancer symposium. Each year nearly 1000 attendees attend this symposium to discuss the latest breakthroughs and emerging topics in prostate cancer treatment and research. The proceedings of this meeting are covered by European Urology (the urology journal with the highest impact factor).
Dr. Tewari is affiliated with over 40 professional associations and organizations, including:
-Member, American Urological Association
-Member, Society of Minimally Invasive Surgery
-Member, Society of Robotic Surgery (SRS)
-Member, Society of Urologic Oncology (SUO)
-Fellow, New York Academy of Medicine
-Associate Editor, AUA News
-Associate Editor, BJUI
-Reviewer, Journal of Urology
-Reviewer, European Urology
- Prostate Cancer
- Prostate-Specific Antigen (PSA) Test
- Robot-Assisted Urologic Procedures
- Robotic Prostate Surgery
Multi-Disciplinary Training AreasBiophysics and Systems Pharmacology [BSP], Cancer Biology [CAB]
MBBS, G.S.V.M. Medical College
Residency, Surgery, G.S.V.M. Medical College
Residency, Urology, Henry Ford Hospital
Fellowship, Transplant, University of Liverpool
Fellowship, Urology Oncology, University of California - San Francisco
Fellowship, Urology Oncology, University of Florida
Fellowship, Urology Oncology, Henry Ford Hospital
Gold Cytoscope Award
First Prize Best Abstract
Most Compassionate Doctor Award
American Society of Clinical Oncology Merit Award
Yahya Cohen Memorial Lecture and Medal
BJU International Visiting Professor Award
America's Best Doctors
- A Continuous Database of Genitourinary Cancer Patients
This is a collection of diagnosis and treatment information of genitourinary cancer cases, including their demographics and cancer related variables obtained from the electronic medical record. This protocol serves as a mechanism to form a database to explore research ideas th...
- PHASE I STUDY OF IN SITU AUTOLOGOUS VACCINATION AGAINST PROSTATECANCER WITH INTRATUMORAL AND SYSTEMIC HILTONOL® (POLY-ICLC) PRIOR TORADICAL PROSTATECTOMY
The purpose of this study is to test an approach of stimulating the body's immune system to attack prostate cancer. To be immune means to be protected. It makes sense that the body system that helps fight off sickness and protects the body is called the immune syst...
- High Resolution MRI/ Multiphoton Microscopy (MPM) Ex vivo Imaging Studies of Prostatic and Peri-prostatic tissue
This study will evaluate the effectiveness of high resolution Magnetic Resonance Imaging (MRI) and Multiphoton Microscopy (MPM) imaging. This imaging research will focus on postoperative prostate specimens and periprostatic tissue obtained from patients who have undergone pros...
- Dissecting Tumor Heterogeneity
This study is designed to dissect tumor heterogeneity (differences) in prostate and kidney cancer. We will focus on two different forms of heterogeneity which are most common.
- First is intratumor heterogeneity (ITH) wherein we will
Nguyen DP, Li J, Yadav SS, Tewari AK. Recent insights into NF-κB signalling pathways and the link between inflammation and prostate cancer. BJU international 2013 Oct;.
Ali A, Nguyen DP, Tewari A. Robot assisted laparoscopic prostatectomy in 2013. Minerva chirurgica 2013 Oct; 68(5).
Kluth LA, Xylinas E, Rieken M, Chun FK, Fajkovic H, Becker A, Karakiewicz PI, Passoni N, Herman M, Lotan Y, Seitz C, Schramek P, Remzi M, Loidl W, Guillonneau B, Rouprêt M, Briganti A, Scherr DS, Graefen M, Tewari AK, Shariat SF. Does increasing the nodal yield improve outcomes in contemporary patients without nodal metastasis undergoing radical prostatectomy?. Urologic oncology 2013 Sep;.
Nguyen DP, Li J, Tewari AK. Inflammation and prostate cancer: the role of interleukin-6. BJU international 2013 Sep;.
Rieken M, Kluth LA, Xylinas E, Seitz C, Fajkovic H, Karakiewicz PI, Lotan Y, Briganti A, Loidl W, Faison T, Crivelli JJ, Scherr DS, Bachmann A, Tewari AK, Kautzky-Willer A, Pummer K, Shariat SF. Impact of statin use on biochemical recurrence in patients treated with radical prostatectomy. Prostate cancer and prostatic diseases 2013 Dec; 16(4).